Abbott has a massive problem to face from the degradation of the Trifecta valves implanted on its patients. Dr. Anita Asgar has chosen DurAVR over the other commercially available valves from Edwards and Medtronic says it all.
Surely Abbott will take a good look at Anteris in particular as Abbott will be focusing on the tissue based valves development to fill the void from the withdrawal of its Trifecta valves. An opportunity too good to miss…
Not advice, DYOR.
- Forums
- ASX - By Stock
- AVR CEO interview on Proactive Investors
AVR
anteris technologies global corp.
Add to My Watchlist
0.00%
!
$6.00

Abbott has a massive problem to face from the degradation of the...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$6.00 |
Change
0.000(0.00%) |
Mkt cap ! $92.99M |
Open | High | Low | Value | Volume |
$6.00 | $6.06 | $6.00 | $12.63K | 2.093K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 83 | $6.00 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$6.09 | 1690 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 83 | 6.000 |
2 | 342 | 5.860 |
2 | 625 | 5.850 |
1 | 857 | 5.830 |
1 | 344 | 5.800 |
Price($) | Vol. | No. |
---|---|---|
6.090 | 1690 | 1 |
6.100 | 927 | 2 |
6.140 | 1490 | 1 |
6.150 | 218 | 1 |
6.160 | 92 | 1 |
Last trade - 11.30am 24/06/2025 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |